It looks to be a longer term study of the Lilac patients on the longer term effects on their health (heart, vitals, weight and other parameters).
Acadia have seemed pretty upbeat on the Trofinetide on their last conference calls are they now planning longer term monitoring studies already?
Primary Outcome Measures :
- Percentage of subjects with treatment-emergent adverse events (TAEs), percentage of subjects with serious adverse events (SAEs), and percentage of subjects withdrawals due to adverse events (AEs) [ Time Frame: 32 months ]
- Number and percentage of subjects with post-Baseline potentially clinically important changes in ECG [ Time Frame: 32 months ]
- Number and percentage of subjects with post-Baseline potentially clinically important changes in vital signs [ Time Frame: 32 months ]
- Number and percentage of subjects with post-Baseline potentially clinically important changes in body weight [ Time Frame: 32 months ]
- Number and percentage of subjects with post-Baseline potentially clinically important changes in laboratory parameters [ Time Frame: 32 months ]
Do your own research.
It looks to be a longer term study of the Lilac patients on the...
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |